Promethera Biosciences Competitors and Similar CompaniesClear all
Promethera Biosciences's competitors and similar companies include Intercept Pharmaceuticals, Poxel and Genfit.
 Promethera Biosciences Promethera Biosciences is a healthcare company developing cell therapy technologies for chronic liver diseases. |  Intercept Pharmaceuticals Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases. |  Poxel Poxelis a research integrated pharmaceutical company that develops products for metabolic diseases. |  Genfit GENFIT is a biopharmaceutical company at the forefront of developing therapeutic and diagnostic solutions to address high unmet patient needs. | |
Founding Date | Founding Date 2009 | Founding Date 2002 | Founding Date 2009 | Founding Date 1999 |
Type | Type Subsidiary | Type Public | Type Public | Type Public |
Tags | ||||
Locations | Locations Mont-Saint-Guibert, BE HQ Charleroi, BE Ganshoren, BE Chuo City, JP Chuo City, JP Basel, CH Durham, US see more | Locations New York, US HQ Wien, AT Mississauga, CA Kongens Lyngby, DK Paris, FR München, DE Dublin, IE see more | Locations Lyon, FR HQ Chiyoda City, JP Cambridge, US | Locations Loos, FR HQ Cambridge, US |
Employees | Employees 185% decrease | Employees 58321% increase | Employees 6 | Employees 180 |
Valuation ($) | Valuation ($) N/A | Valuation ($) 794.7 m | Valuation ($) 18.3 m | Valuation ($) 280.8 m |
Financial | ||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) $285.7m (FY, 2022) | Revenue (est.) €6.6m (FY, 2024) | Revenue (est.) €65.4m (FY, 2025) |
Cost of goods | Cost of goods N/A | Cost of goods $984k (FY, 2022) | Cost of goods €2.8m (FY, 2024) | Cost of goods €302k (FY, 2025) |
Gross profit | Gross profit N/A | Gross profit $284.7m (FY, 2022) | Gross profit €3.8m (FY, 2024) | Gross profit €70.8m (FY, 2025) |
Net income | Net income N/A | Net income $221.8m (FY, 2022) | Net income (€18.3m) (FY, 2024) | Net income (€86m) (FY, 2025) |
Funding | ||||
Total funding raised | Total funding raised $ 146m | Total funding raised $ 55m | Total funding raised $ 33.8m | Total funding raised N/A |
For sources of this data, please see the company profile
View Company Profiles
Intercept Pharmaceuticals
HQ
New York, US
Employees
583↑ 21% increase
Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases.
View companyPoxel
HQ
Lyon, FR
Employees
6
Poxelis a research integrated pharmaceutical company that develops products for metabolic diseases.
View companyGenfit
HQ
Loos, FR
Employees
180
GENFIT is a biopharmaceutical company at the forefront of developing therapeutic and diagnostic solutions to address high unmet patient needs.
View company